V. Martins

发表

4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.

Mike Wood, Brian Dymock, Xavier Barril, 2007, Journal of medicinal chemistry.

Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Discovery of a Non-Alanine Lead Series with Dual Activity Against cIAP1 and XIAP.

G. Chessari, P. Williams, E. J. Lewis, 2015, Journal of medicinal chemistry.

NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis.

L. Pearl, X. Barril, M. Drysdale, 2008, Cancer research.

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

Mitch Dowsett, Gerhardt Attard, Johann S de Bono, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity

P. Workman, F. Chan, R. T. te Poele, 2007, Molecular Cancer Therapeutics.

Dependence of Wilms tumor cells on signaling through insulin-like growth factor 1 in an orthotopic xenograft model targetable by specific receptor inhibition

Chris Jones, F. Hofmann, S. Robinson, 2012, Proceedings of the National Academy of Sciences.

Cancer Therapy : Preclinical AT 13148 Is a Novel , Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

P. Jones, P. Workman, M. Walton, 2012 .

AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

P. Jones, P. Workman, M. Walton, 2012, Clinical Cancer Research.

Discovery of a Potent Nonpeptidomimetic, Small-Molecule Antagonist of Cellular Inhibitor of Apoptosis Protein 1 (cIAP1) and X-Linked Inhibitor of Apoptosis Protein (XIAP).

G. Chessari, P. Williams, E. Chiarparin, 2017, Journal of medicinal chemistry.

Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate.

P. Workman, A. Faisal, R. Bayliss, 2010, Journal of medicinal chemistry.

Efficacy of Clinically Used PARP Inhibitors in a Murine Model of Acute Lung Injury

C. Szabó, R. Salomão, L. Liaudet, 2022, Cells.

Crossover pharmacokinetics (PK) study to assess oral administration of abiraterone acetate capsule and tablet formulations in fasted and fed states in patients with prostate cancer

Robin L. Jones, F. Kabbinavar, F. Raynaud, 2008 .

A Fragment-Derived Clinical Candidate for Antagonism of X-Linked and Cellular Inhibitor of Apoptosis Proteins: 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1 H,2 H,3 H-pyrrolo[3,2- b]pyridin-1-yl)-2-[(2 R,5 R)-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one

G. Chessari, P. Williams, G. Saxty, 2018, Journal of medicinal chemistry.

Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors.

Christopher W Murray, Paul N. Mortenson, Valerio Berdini, 2015, ACS medicinal chemistry letters.

Enhanced Efficacy of IGF1R Inhibition in Pediatric Glioblastoma by Combinatorial Targeting of PDGFRα/β

Chris Jones, F. Hofmann, S. Jeay, 2011, Molecular Cancer Therapeutics.

Preclinical Development Enhanced Efficacy of IGF 1 R Inhibition in Pediatric Glioblastoma by Combinatorial Targeting of PDGFR a / b

Chris Jones, F. Hofmann, S. Jeay, 2011 .

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

P. Kantoff, E. Small, J. Rosenberg, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer

D. Longley, P. Dunne, M. Lawler, 2020, Molecular Cancer Therapeutics.

ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth

G. Chessari, J. Lyons, N. Thompson, 2018, Molecular Cancer Therapeutics.

ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK

C. Murray, V. Berdini, J. Lyons, 2021, Molecular Cancer Therapeutics.

Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2.

C. Murray, V. Berdini, L. Fazal, 2021, Journal of medicinal chemistry.

Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2.

C. Murray, V. Berdini, J. Castro, 2018, Journal of medicinal chemistry.

MiR-139-5p is a potent tumor suppressor in adult acute myeloid leukemia

H. Kestler, L. Bullinger, K. Döhner, 2016, Blood Cancer Journal.

Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer

D. Longley, P. Dunne, M. Lawler, 2020, Molecular Cancer Therapeutics.

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

M. Dowsett, D. Dearnaley, C. Parker, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

P. Jones, P. Workman, M. Walton, 2012, Clinical Cancer Research.